Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,734,137 | Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine In force · Medium confidence | Zogenix International Limited | In force | Medium confidence | ||
| Application 15/246,346 | Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine Abandoned Abandoned Jul 6, 2020 | Zogenix International Limited | Abandoned | Abandoned Jul 6, 2020 | ||
| Application 18/418,121 | Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine Pending Not granted | Zogenix International Limited | Pending | Not granted | ||
| Application 18/418,133 | Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine Pending Not granted | Zogenix International Limited | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Zogenix, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.